Share Email Print

Journal of Biomedical Optics

Monitoring early tumor response to drug therapy with diffuse optical tomography
Author(s): Molly L. Flexman; Fotios Vlachos; Hyun-Keol Kim; Andreas H. Hielscher; Shashank R. Sirsi; Mark A. Borden; Jianzhong Huang; Tessa B. Johung; Jeffrey W. Gander; Ari R. Reichstein; Darrell J. Yamashiro; Jessica J. Kandel; Sonia L. Hernandez; Brooke S. Lampl; Antai Wang
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy-thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.

Paper Details

Date Published: 8 February 2012
PDF: 9 pages
J. Biomed. Opt. 17(1) 016014 doi: 10.1117/1.JBO.17.1.016014
Published in: Journal of Biomedical Optics Volume 17, Issue 1
Show Author Affiliations
Molly L. Flexman, Columbia Univ. (United States)
Fotios Vlachos, Columbia Univ. (United States)
Hyun-Keol Kim, Columbia Univ. (United States)
Andreas H. Hielscher, Columbia Univ. (United States)
Shashank R. Sirsi, Columbia Univ. (United States)
Mark A. Borden, Columbia Univ. (United States)
Jianzhong Huang, Univ. of Colorado at Boulder (United States)
Tessa B. Johung, Univ. of Colorado at Boulder (United States)
Jeffrey W. Gander, Univ. of Colorado at Boulder (United States)
Ari R. Reichstein, Univ. of Colorado at Boulder (United States)
Darrell J. Yamashiro, Univ. of Colorado at Boulder (United States)
Jessica J. Kandel, Univ. of Colorado at Boulder (United States)
Sonia L. Hernandez, Columbia Univ. Medical Ctr. (United States)
Brooke S. Lampl, Columbia Univ. Medical Ctr. (United States)
Antai Wang, Columbia Univ. (United States)

© SPIE. Terms of Use
Back to Top